Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 194-209 http://medscipublisher.com/index.php/cge 198 The non-invasive detection of ncRNAs in blood or other body fluids offers a promising approach for early cancer detection and monitoring. These molecules can provide valuable insights into the molecular mechanisms underlying cancer progression and resistance to therapy. As research advances, ncRNAs are expected to become integral components of liquid biopsy strategies, aiding in the development of personalized treatment plans and improving patient outcomes. 3.5 Protein biomarkers Protein biomarkers are specific proteins whose expression levels are altered in cancer cells and can be detected in body fluids such as blood, urine, or stool. These biomarkers provide valuable information about the presence, stage, and progression of colon cancer. Several protein biomarkers have been identified for colon cancer diagnosis and monitoring, offering non-invasive alternatives to traditional diagnostic methods. One of the most well-known protein biomarkers for colon cancer is carcinoembryonic antigen (CEA), which is widely used in clinical practice to monitor disease progression and response to treatment. Elevated levels of CEA are associated with advanced stages of colon cancer and poor prognosis. However, CEA alone is not sufficient for early detection, necessitating the identification of additional protein biomarkers. Recent studies have identified several promising protein biomarkers for colon cancer. For example, Wusterbarth et al. (2021) found that Cartilage Oligomeric Matrix Protein (COMP) is overexpressed in colon cancer tissues and correlates with tumor aggressiveness and poor survival outcomes. Similarly, Zhang et al. (2019) identified Chromogranin A (CHGA) as a novel biomarker for early detection of colon cancer, showing strong diagnostic potential. Combining multiple protein biomarkers can enhance the sensitivity and specificity of cancer detection. Bhardwaj et al. (2020) demonstrated that a panel of protein markers, including COMP and CHGA, could significantly improve early detection of colorectal cancer. The integration of these biomarkers into clinical practice offers a non-invasive, accurate, and cost-effective approach for colon cancer diagnosis and monitoring, potentially improving patient outcomes through earlier detection and personalized treatment strategies. 4 Techniques for Detecting Non-Invasive Biomarkers 4.1 Liquid biopsy Liquid biopsy is a transformative approach for non-invasive cancer diagnosis and monitoring, utilizing body fluids like blood, urine, and saliva to detect tumor-derived materials. This method primarily targets circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles such as exosomes. ctDNA analysis can reveal tumor-specific mutations, copy number variations, and methylation patterns, providing a comprehensive overview of the tumor's genetic landscape. CTCs offer insights into tumor metastasis, and their enumeration is a prognostic indicator in colorectal cancer. Exosomes, which carry DNA, RNA, and proteins, reflect the molecular state of their cell of origin and are valuable for biomarker discovery. Liquid biopsy allows for real-time monitoring of tumor dynamics, assessment of minimal residual disease, and detection of recurrence, enhancing personalized treatment strategies. Studies have shown that liquid biopsy can detect colorectal cancer at an early stage, with high sensitivity and specificity, making it a promising tool for early diagnosis and monitoring treatment response (Iwasaki et al., 2022). Moreover, liquid biopsy is less invasive than traditional tissue biopsies, reducing patient discomfort and risk. 4.2 Next-Generation sequencing (NGS) Next-Generation Sequencing (NGS) is a cutting-edge technology that enables the comprehensive sequencing of DNA and RNA with high throughput and precision. NGS is employed in the detection of non-invasive biomarkers by analyzing circulating tumor DNA (ctDNA) and cell-free RNA (cfRNA) in blood samples. This technique allows for the identification of specific genetic mutations, gene fusions, and other alterations that are characteristic of colorectal cancer. By sequencing millions of DNA or RNA fragments simultaneously, NGS provides a detailed genomic and transcriptomic landscape of the tumor, which is crucial for personalized medicine. NGS can identify rare mutations and genetic variants that may be missed by traditional methods, offering a more sensitive and specific approach to cancer diagnosis. Studies have demonstrated that NGS-based assays can detect
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==